Bharat Biotech seeks DCGI nod for study of intra-nasal COVID vaccine as booster dose
New Delhi: Indian vaccine maker Bharat Biotech said on Monday it has submitted an application to the country's drug regulator to conduct a late-stage trial for a booster dose of its intranasal COVID-19 vaccine.
Key Attributes of intranasal COVID vaccine:
. An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.
. Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.
Covaxin, the company's COVID-19 vaccine already approved for emergency-use approval in the county, is administered through an injection.
Coronavirus cases in India have fallen sharply since a devastating second wave earlier this year. The South Asian nation has detected over 100 cases of the Omicron variant so far.
Bharat Biotech International Limited is an Indian multinational biotechnology company headquartered in Genome Valley, Turakapally, Hyderabad. The company was founded by Krishna Ella in 1996.
Read also: Bharat Biotech study on Covaxin, nasal COVID jab cocktail gets DCGI nod: Report
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.